Mandate

Vinge advises Ottobock on its acquisition of Exoneural Network AB

Vinge advises Ottobock, a portfolio company to EQT, on its acquisition of Exoneural Network AB a Swedish startup that has developed the so called Exopulse Mollii Suit.

The suit covers the entire body and uses electrostimulation to relax tense or spastic muscles which can improve the mobility for people with spastic diseases. Ottobock is an international medtech company and the acquisition is a step towards the expansion of its portfolio for promising neuro-orthotics.

Vinge’s team consisted of, among others, partner Christina Kokko, associates Stina Bengtsson, Jesper Lindvall and Annie Fällström (M&A), Sara Strandberg and Carl Östlund (Employment), Stojan Arnerstål och Sofia Bergenstråhle (IP), Mika Jordan (IT & GDPR), Christoffer Nordin (Regulatory) Fredrika Hjelmberg and Carla Zachariasson (Commercial Agreements) Tove Lövgren Frisk (Compliance) and Carl Bruneheim (Project assistant).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025